Key facts
- It has raised $25.5M across 1 recorded rounds; the latest was Early Stage VC ($24.5M) in Mar 2022.
- Notable investors include Alumni Ventures, 8VC, National Institutes of Health, Endless Frontier Labs, Harvard Innovation Launch Lab — 26 tracked in total.
- Concerto Biosciences has filed 2 Form Ds with the SEC, most recently Jun 2022 ($24.5M sold to 37 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 26 names
- ·Watchlist + deal alerts for Concerto Biosciences
Funding rounds
1 roundsAbout Concerto Biosciences
Developer of microbe-based products intended for novel functions in agriculture and human health. The company discovers and develops microbial ensembles with specific combinations of microbes that accomplish useful functions in human health, agriculture and industry, enabling researchers to address urgent global challenges in a range of markets from the food industry to healthcare.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2019
- Employees
- 32
- Website
- concertobio.com/
- Ownership
- Privately Held (backing)
Concerto Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Concerto Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Concerto Biosciences in its N-PORT filings yet. We sweep new filings monthly.